19 completed, 3 not yet recruiting, 3 recruiting, 3 unknown. 30 Phase 2, 5 Phase 3, 3 Phase 1.
Follow Calcinosis: new trials by email Literature Review of Calcinosis trials Research Report on Calcinosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of EPN-701 for the Treatment of Calciphylaxis EPN-701 (Oral), Placebo (Normal Saline) - Calciphylaxis | Phase 2 | Not yet recruiting | Sagar U. Nigwekar, MD, MMSc | 60 | 2026-12-07 | 2026-11-10 |
| REducing Systemic Inflammation With LOw-dose Colchicine to ImproVE Cardiovascular Calcification in Chronic Kidney Disease: A Pilot Randomized Open-Label Trial Low-dose Colchicine at 0.5mg daily, Usual Care - Chronic Kidney Disease Mineral and Bone Disorder, Cognitive Function | Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 60 | 2026-10-30 | 2026-11-04 |
| The GranStone Trial empagliflozin (Jardiance) 25 mg, Losartan 100 mg - Paraffinoma, Granuloma, Foreign-Body | Phase 2 / Phase 3 | Recruiting | Martin Blomberg Jensen | 100 | 2026-10-20 | 2026-11-10 |
| Pentoxifylline for Vascular Calcification in Kidney Disease Pentoxifylline 400 MG Oral Tablet, Conventional Medications for Chronic Kidney Disease - Chronic Kidney Disease, Vascular Calcification | Phase 1 / Phase 2 | Not yet recruiting | Mansoura University | 80 | 2025-04-15 | 2025-04-01 |
| Intralesional Injection of STS in Treatment of Calcinosis Sodium Thiosulfate (STS) - Systemic Sclerosis (SSc), Dermatomyositis | Phase 2 | Recruiting | Robyn T. Domsic, MD, MPH | 20 | 2025-03-17 | 2026-05-05 |
| Safety and Efficacy of Topical Sodium Metabisulfite for the Treatment of Calcinosis in Patients With Systemic Sclerosis Topical 25% sodium metabisulfite (SM) in pediatric cold cream, Placebo - Systemic Sclerosis, Calcinosis | Phase 1 / Phase 2 | Unknown | Pontificia Universidad Catolica de Chile | 20 | 2024-01-02 | 2023-12-04 |
| Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Fluconazole in Hypercalcicuric Patients With Increased 1.25(OH) 2D Levels Fluconazole, Placebo - Nephrolithiasis, Nephrocalcinosis | Phase 2 | Completed | Hospices Civils de Lyon | 56 | 2021-01-13 | 2024-07-12 |
| The Effect of Etelcalcetide on CKD-MBD Etelcalcetide - Chronic Kidney Disease Mineral and Bone Disorder, Renal Osteodystrophy | Phase 2 | Completed | Thomas Nickolas, MD MS | 22 | 2018-09-06 | 2023-09-21 |
| Rifampin in CYP24A1-related Hypercalcemia and Hypercalciuria Rifampin - Idiopathic Infantile Hypercalcaemia - Severe Form, Genetic Disease | Phase 2 | Recruiting | Children's Hospital of Philadelphia | 60 | 2018-07-25 | 2026-10-13 |
| Cholecalciferol on Hemodialysis Patients Cholecalciferol, Placebo - Hemodialysis Complication, Vitamin D Deficiency | Phase 2 / Phase 3 | Completed | Ain Shams University | 60 | 2018-07-01 | 2019-01-09 |
| Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis Sodium Thiosulfate - Dermatomyositis, Idiopathic Inflammatory Myopathies | Phase 2 / Phase 3 | Completed | National Institute of Environmental Health Sciences (NIEHS) | 15 | 2017-10-05 | 2024-11-26 |
| Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD) SNF472, Placebo - Cardiovascular Diseases, Cardiovascular Abnormalities | Phase 2 | Completed | Sanifit Therapeutics S. A. | 274 | 2016-11-01 | 2021-04-15 |
| Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis Oral treprostinil - Systemic Sclerosis, Calcinosis | Phase 2 | Completed | Stanford University | 12 | 2016-10-01 | 2021-06-10 |
| Treatment to Reduce Vascular Calcification in Hemodialysis Patients Using Vitamin K menaquinone-7 - Vascular Calcification, Systemic and Arterial Stiffness | Phase 2 | Completed | National University Health System, Singapore | 178 | 2016-07-01 | 2023-01-17 |
| Phase 2 Study With SNF472 in Calciphylaxis Patients SNF472 - Calciphylaxis, Calcific Uremic Arteriolopathy | Phase 2 | Completed | Sanifit Therapeutics S. A. | 14 | 2016-05-01 | 2019-08-28 |
| Effect of Oral Magnesium on Vascular Calcification in Chronic Kidney Disease Mablet 360 mg, Placebo - Chronic Kidney Disease, Vascular Calcification | Phase 2 | Completed | Nordsjaellands Hospital | 148 | 2015-11-01 | 2022-09-06 |
| A Study Evaluating the Effects of Ataciguat (HMR1766) on Aortic Valve Calcification Ataciguat (HMR1766), Placebo Comparator: Matching Placebo - Aortic Valve Stenosis | Phase 2 | Completed | Mayo Clinic | 35 | 2015-06-01 | 2021-01-22 |
| ACTHAR GEL for Sarcoidosis-Associated Calcium Dysregulation: An Open-label Pilot Study ACTHAR Gel (adrenocorticotropic hormone) - Sarcoidosis, Hypercalcemia Due to Sarcoidosis | Phase 2 / Phase 3 | Unknown | Albany Medical College | 10 | 2015-02-01 | 2015-01-26 |
| Exparel as a Nerve Block for Severe Hand Pain liposomal bupivacaine - CREST Syndrome, Peripheral Vascular Disease | Phase 2 / Phase 3 | Terminated | Jose Soberon, MD | 13 | 2014-11-01 | 2024-05-21 |
| Bone Mass and Strength After Kidney Transplantation Vitamin D3, Calcitriol, Placebo - End Stage Renal Disease, Kidney Transplantation | Phase 2 | Completed | Columbia University | 61 | 2014-08-18 | 2025-03-07 |
Showing 20 of 30. Sign in to see all of them.
Vascular Calcification (12) · Kidney Failure, Chronic (5) · Renal Insufficiency, Chronic (5) · Hypercalcemia (4) · Nephrocalcinosis (4) · Dermatomyositis (3) · Hypercalciuria (3) · Hyperparathyroidism (3) · Nephrolithiasis (3) · Scleroderma, Systemic (3) · Bone Diseases (2) · Calciphylaxis (2) · Cardiovascular Diseases (2) · Chronic Kidney Disease-Mineral and Bone Disorder (2)
Nutritional and Metabolic Diseases (30) · Calcium Metabolism Disorders (29) · Metabolic Diseases (29) · Pathological Conditions, Signs and Symptoms (14) · Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Male Urogenital Diseases (12) · Urogenital Diseases (12) · Urologic Diseases (12) · Kidney Diseases (11) · Pathologic Processes (11) · Disease Attributes (10) · Chronic Disease (9) · Skin and Connective Tissue Diseases (9)
sodium thiosulfate (5) · Cholecalciferol (2) · SNF472 (2) · 5-chloro-2-(5-chlorothiophene-2-sulfonylamino)-N-(4-(morpholine-4-sulfonyl)phenyl)benzamide (1) · Adrenocorticotropic Hormone (1) · Calcitonin (1) · Calcitriol (1) · Etidronic Acid (1) · Fluconazole (1) · Lasers (1) · Losartan (1) · Magnesium Oxide (1) · Magnetic Resonance Imaging (1) · Pentoxifylline (1) · Rifampin (1)
Ramathibodi Hospital (2) · Sanifit Therapeutics S. A. (2) · Ain Shams University (1) · Albany Medical College (1) · Alison Ehrlich (1) · Children's Hospital of Philadelphia (1) · Columbia University (1) · Dr. Rachel Holden (1) · Hospices Civils de Lyon (1) · Jose Soberon, MD (1) · Loyola University (1) · Mansoura University (1) · Mark Lebwohl (1) · Martin Blomberg Jensen (1) · Mayo Clinic (1)
United States (17) · China (2) · Denmark (2) · Thailand (2) · United Kingdom (2) · Canada (1) · Chile (1) · Egypt (1) · France (1) · Norway (1) · Singapore (1) · Spain (1)
Thomas Nickolas, MD, MS (2) · Adam I Schiffenbauer, M.D. (1) · Alessandra Brofferio, M.D. (1) · Alex Gold, MD (1) · Alison Ehrlich, MD (1) · Andrea Morris, MD (1) · Antonia Valenzuela, MD, MS (1) · Chengxiang Li, M.D., Ph.D. (1) · Craig B. Langman (1) · Elaine Adams, M.D. (1) · Gary Simon, MD (1) · Gulnara Mamayrova, MD (1) · Haitang Hu, MD (1) · Iain O Bressendorff, MD, PhD (1)
PMID 15942915, PMID 22227955, PMID 26075081, PMID 28645983, PMID 31707860, PMID 32899022, PMID 33594986, PMID 33835939, PMID 34718447, PMID 35641194, PMID 35710560, PMID 36749131, PMID 37574661, PMID 38326858, PMID 38384289, PMID 38568107, PMID 39989354
P50AR080612 (1), R01DK112955 (1)